Tag: bioCSL global influenza vacine industry
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Reducing downtime through real-time shop floor insights with Minitab’s Prolink
Unplanned downtime remains one of the most costly – and often misunderstood – challenges on the manufacturing floor.
